At US Oncology Research’s recent Annual Science Forum, Rocky Mountain Cancer Centers was the recipient of the Highest Accruing Site Award, having more than 1,900 patients in clinical trials. The event highlighted the importance of clinical trials as a treatment option, as well as recognized individuals and practices who have demonstrated a major commitment to making clinical trials available to patients.
“Clinical investigation is critical for evaluating new treatments and combinations of therapies that may provide more promising treatment options for patients,” said Allen Cohn, MD, site research leader for RMCC. “Our patients who participate in these trials are the true champions of clinical research who bravely step forward into unknown territory. They play a key role in advancing the fight against cancer, and all of us in the cancer community owe them a great debt of gratitude.”
US Oncology Research, supported by McKesson Specialty Health and The US Oncology Network, is one of the largest community-based oncology research programs in the United States specializing in oncology clinical trials. Physicians affiliated with US Oncology Research have enrolled more than 61,000 patients in over 1,400 clinical trials. The organization has played a role in more than 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date, including eight in the past 12 months.